Phase 2 Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

Purpose

To test whether bupropion, a medication that is approved for depression and smoking cessation, can improve sexual desire compared to placebo

Criteria

Post-menopausal women 18 year of age or older that have been diagnosed with breast or gynecologic cancer and have completed all therapy consisting of surgery, chemotherapy or radiation therapy at least 180 days prior to study entry.   

You Cannot:           

Have a diagnosis of depression, Major Depressive Disorder (MDD), suicidal ideations or anxiety disorders in the past 5 years.

Have seizure disorder

Have current or history of anorexia or bulimia in the past 5 years.

Have Stage IV cancer

Use oral or transdermal estrogen therapy

Details

This study will last a total of 10 weeks.

This study has 3 study groups.

2 different doses of bupropion (150mg & 300mg), & placebo

Each group will be supplied with 4 bottles of pills which will come in a kit with an instruction sheet.

1 pill will be taken each morning for 1 week, then 2 pills each morning for 8 weeks, and then 1 pill each morning for 1 week

Those that are assigned to the placebo only group, will be given the option to try the study drug, provided by the study.

Those that choose to participate will take bupropion for a total of 8 additional weeks after completing the first 10 weeks of study treatment.

Interested in more information? Contact Us:

Radiation Oncology Services

IRB: National Cancer Institute led by NRG Oncology
IRB Number:
Trial Type: NA
Sponsor: National Cancer Institute led by NRG Oncology